Clinical Trials Logo

Hematological Malignancies clinical trials

View clinical trials related to Hematological Malignancies.

Filter by:

NCT ID: NCT05728658 Recruiting - Clinical trials for Hematological Malignancies

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Start date: March 9, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ICP-248 in patients with mature B-cell malignancies. This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period

NCT ID: NCT05475600 Recruiting - Anxiety Clinical Trials

APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU

APAER_H
Start date: December 2, 2022
Phase: N/A
Study type: Interventional

Adapted Physical Activity (APA) is accepted as an effective, recommended and beneficial supportive care for the health of people with cancer during the different phases of the disease. The objective of the project is to analyse the effect of APA programs (Classic, Exergaming and Relaxation) on the state anxiety of people with severe blood diseases admitted to Intensive Care Unit (ICU). Anxiety is a major affect in this context. The interest of the practice of APA for this public is to reduce the level of state anxiety and to limit the decline of functional capacities. The main objective of this work is to identify whether specific and/or complementary effects result from the use of biofeedback and/or Exergaming.

NCT ID: NCT05454241 Recruiting - Clinical trials for Hematological Malignancies

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Start date: September 7, 2022
Phase: Phase 2
Study type: Interventional

This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.

NCT ID: NCT05347225 Active, not recruiting - Clinical trials for Hematological Malignancies

A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

Start date: June 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.

NCT ID: NCT05338346 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

ATRIUM
Start date: July 8, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies .

NCT ID: NCT05306509 Recruiting - Solid Tumor Clinical Trials

Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology

NiCE
Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study aims to develop and implement a pediatric palliative care (PPC) program. It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's Hospital of Fudan University. The intervention group will receive Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE). The control group will receive routine PPC (will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment). The intervention will take 6 months.

NCT ID: NCT05290545 Recruiting - Clinical trials for Hematopoietic Stem Cell Transplantation

Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

Start date: February 15, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study was to explore whether the combination with umbilical cord blood (UCB) is associated with superior disease-free survival (DFS) in the setting of haploidentical donors (HID) transplantation.

NCT ID: NCT05103995 Completed - Clinical trials for Hematological Malignancies

Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation

Start date: January 1, 2013
Phase:
Study type: Observational

the impact of donor-recipient ABO matching on outcome of peripheral blood stem cell haploidentical hematopoietic stem cell transplantation

NCT ID: NCT05020639 Recruiting - Clinical trials for Hematological Malignancies

A Study of TQB3820 in Patients With Hematological Malignancies

Start date: August 31, 2021
Phase: Phase 1
Study type: Interventional

TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects of the immune dysregulation mediated by B cells.

NCT ID: NCT05005442 Active, not recruiting - Clinical trials for Hematological Malignancies

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Start date: September 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the safety and tolerability of pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also evaluate the overall response rate (ORR), the duration of response (DOR), and disease control rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).